<DOC>
	<DOCNO>NCT01484990</DOCNO>
	<brief_summary>A Pharmacokinetic Study Levodopa Carbidopa Intestinal Gel Subjects Advanced Parkinson 's Disease .</brief_summary>
	<brief_title>A Pharmacokinetic Study Levodopa Carbidopa Intestinal Gel Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female subject least 30 year old ; 2 . Subjects advance Parkinson 's disease already LCIG ( DuodopaÂ® ) least 30 day ; 3 . Body mass index range 18.0 30.0 kg/m2 Exclusion Criteria 1 . Subjects consider violent subject consider suicidal risk investigator ; 2 . Clinically significant abnormal laboratory data baseline abnormal laboratory value could interfere study assessment ; 3 . Subjects serious symptomatic cerebral disease , cerebrovascular disease , focal neurological lesion ( previous brain surgery ) , acute brain trauma require treatment anticonvulsant therapy , acute stroke</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>carbidopa</keyword>
	<keyword>Duodopa</keyword>
	<keyword>intestinal gel</keyword>
</DOC>